HER2 Low Expression in Primary Male Breast Cancer

References

• Cardoso F, Bartlett JMS, Slaets L, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol. 2018;29(2):405–417. doi:10.1093/annonc/mdx651
   PubMed Web of Science ®Google Scholar
• Nilsson C, Johansson I, Ahlin C, et al. Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact. Acta Oncol. 2013;52(1):102–109. doi:10.3109/0284186X.2012.711952
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–182. doi:10.1126/science.3798106
   PubMed Web of Science ®Google Scholar
• Hamilton E, Shastry M, Shiller SM, Ren R. Targeting HER2 heterogeneity in breast cancer. Cancer Treat Rev. 2021;100:102286. doi:10.1016/j.ctrv.2021.102286
   PubMed Web of Science ®Google Scholar
• Marchio C, Annaratone L, Marques A, Casorzo L, Berrino E, Sapino A. Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond. Semin Cancer Biol. 2021;72:123–135. doi:10.1016/j.semcancer.2020.02.016
   PubMed Web of Science ®Google Scholar
• Dieci MV, Miglietta F. HER2: a never ending story. Lancet Oncol. 2021;22(8):1051–1052. doi:10.1016/S1470-2045(21)00349-1
   PubMed Web of Science ®Google Scholar
• Wolff AC, Somerfield MR, Dowsett M, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists Guideline Update. J Clin Oncol. 2023:JCO2202864. doi:10.1200/JCO.22.02864
   Web of Science ®Google Scholar
• Ponde N, Brandao M, El-Hachem G, Werbrouck E, Piccart M. Treatment of advanced HER2-positive breast cancer: 2018 and beyond. Cancer Treat Rev. 2018;67:10–20. doi:10.1016/j.ctrv.2018.04.016
   PubMed Web of Science ®Google Scholar
• Nicolo E, Boscolo Bielo L, Curigliano G, Tarantino P. The HER2-low revolution in breast oncology: steps forward and emerging challenges. Ther Adv Med Oncol. 2023;15:17588359231152842. doi:10.1177/17588359231152842
   Web of Science ®Google Scholar
• Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387(1):9–20. doi:10.1056/NEJMoa2203690
   PubMed Web of Science ®Google Scholar
• Mosele F, Deluche E, Lusque A, et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the Phase 2 DAISY trial. Nat Med. 2023;29(8):2110–2120. doi:10.1038/s41591-023-02478-2
   PubMed Web of Science ®Google Scholar
• Corti C, Giugliano F, Nicolo E, Tarantino P, Criscitiello C, Curigliano G. HER2-low breast cancer: a new subtype? Curr Treat Options Oncol. 2023;24(5):468–478. doi:10.1007/s11864-023-01068-1
   PubMed Web of Science ®Google Scholar
• Sinn HP, Helmchen B, Wittekind CH. TNM-Klassifikation beim Mammakarzinom: neuerungen und Anmerkungen zur 7. Auflage [TNM classification of breast cancer: changes and comments on the 7th edition]. Pathologe. 2010;31(5):361–366. German. doi:10.1007/s00292-010-1307-0
   PubMedGoogle Scholar
• Wittekind C. Regionare Lymphknoten, Satelliten und TNM: werden wir besser? 7. Edition der UICC 2010 zur TNM-Klassifikation maligner Tumoren [Lymph nodes, tumour deposits, and TNM: are we getting better? 7th edition of UICC 2010 TNM classification of malignant tumors]. Strahlenther Onkol. 2012;188(2):191–192. German. doi:10.1007/s00066-011-0032-9
   PubMedGoogle Scholar
• Remmele W, Stegner HE. Vorschlag zur einheitlichen Definition eines Immunreaktiven Score (IRS) fur den immunhistochemischen Ostrogenrezeptor-Nachweis (ER-ICA) im Mammakarzinomgewebe [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe. 1987;8(3):138–140. German.
   PubMed Web of Science ®Google Scholar
• Erices-Leclercq M, Lubig S, Forster F, et al. Prognostic relevance of Ki67 expression in primary male breast cancer: determination of cut-off points by different evaluation methods and statistical examinations. J Cancer Res Clin Oncol. 2022;148(2):441–447. doi:10.1007/s00432-021-03623-5
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–1672. doi:10.1056/NEJMoa052306
   PubMed Web of Science ®Google Scholar
• Rudlowski C, Rath W, Becker AJ, Wiestler OD, Buttner R. Trastuzumab and breast cancer. N Engl J Med. 2001;345(13):997–998.
   PubMedGoogle Scholar
• Tarantino P, Hamilton E, Tolaney SM, et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol. 2020;38(17):1951–1962. doi:10.1200/JCO.19.02488
   PubMed Web of Science ®Google Scholar
• Tarantino P, Jin Q, Tayob N, et al. Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer. JAMA Oncol. 2022;8(8):1177–1183. doi:10.1001/jamaoncol.2022.2286
   PubMed Web of Science ®Google Scholar
• Giugliano F, Curigliano G, Tarantino P. HER2-low expression in breast oncology: treatment implications in the smart chemotherapy era. Eur J Cancer Prev. 2023;32(2):149–154. doi:10.1097/CEJ.0000000000000781
   PubMed Web of Science ®Google Scholar
• Jylling AMB, Jensen V, Lelkaitis G, Christiansen P, Nielsen SS, Lautrup MD. Male breast cancer: clinicopathological characterization of a National Danish cohort 1980–2009. Breast Cancer. 2020;27(4):683–695. doi:10.1007/s12282-020-01066-3
   PubMed Web of Science ®Google Scholar
• Rudlowski C, Friedrichs N, Faridi A, et al. Her-2/neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res Treat. 2004;84(3):215–223. doi:10.1023/B:BREA.0000019953.92921.7e
   PubMed Web of Science ®Google Scholar
• Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021;22(8):1151–1161. doi:10.1016/S1470-2045(21)00301-6
   PubMed Web of Science ®Google Scholar
• Nicolo E, Tarantino P, Curigliano G. Biology and treatment of HER2-low breast cancer. Hematol Oncol Clin North Am. 2023;37(1):117–132. doi:10.1016/j.hoc.2022.08.013
   PubMed Web of Science ®Google Scholar